Wintermute is Now Recruiting Patients for the ZosterEase Phase Ib Clinical Trial. Read more .

Novel & safe therapies for infectious diseases

Harnessing the antimicrobial power
of fatty acids

Solexan™: Our topical therapy for shingles


At Wintermute Biomedical, our mission is to develop safe and effective next-generation therapies to combat infectious diseases.

A next-generation platform to unlock the antimicrobial power of fatty acids

Fatty acids have strong antibacterial, antifungal, and antiviral activity. But their lack of solubility in water poses a challenge to using them in a clinical setting. We have developed a powerful, next-generation, and safe solution to this; by using amino acids, part of everyday foods, we have figured out a way to get the fatty acids to solubilize in water to unlock the power of fatty acids. We are leveraging this patented platform to let fatty acids shine. This platform opens the door to a multitude of applications in healthcare.

Learn more

Solexan™ as a topical treatment for shingles

Our main project is developing an undecylenic acid-based formulation, Solexan™, as a therapy for shingles. Solexan™ has been FDA-registered as a topical antifungal, meaning our safety profile is already established, allowing us to fast-track Solexan™ into efficacy trials. We are currently preparing for a Phase I trial to validate the safety of Solexan™ in shingles patients.

Learn more

Novel treatments for antibiotic-resistant diseases like Impetigo and more

We don’t want to stop at shingles. Every single day, more and more patients fall victim to infectious diseases and antimicrobial resistance (AMR) is making treatment difficult. New therapies are desperately needed to combat drug-resistant bacteria and new strains of micro-organisms to improve health outcomes for individuals and society at large. We’ve seen that our formulations of fatty acids have powerful activity against many bacterial-borne diseases like Impetigo, caused by Staphylococcus aureus.

Learn more